Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma

In a period marked by intensifying global competition and a broad reshaping of the pharmaceutical industry, the wave of job cuts sweeping across major drugmakers continues to draw attention. Novo Nordisk’s recent announcement of cutting approximately 9,000 jobs globally, representing about 11.5% of its workforce, stands out as a defining instance of strategic contraction paired with resource concentration. 

For the Danish company, long celebrated for its blockbuster GLP-1 medications such as Semaglutide—marketed under brand names like Ozempic and Wegovy—this restructuring is not a mere cost-cutting exercise. It is a deep strategic pivot, introduced under newly appointed CEO Maziar Mike Doustdar, to respond proactively to evolving market dynamics. 

Doustdar assumed the leadership of Novo Nordisk just as the company faced a series of headwinds: the GLP-1 market was becoming crowded, growth for its core products was decelerating, and the China market for the diabetes injection version even recorded a decline. The stock had tumbled nearly 60% within a year, erasing hundreds of billions in market value. For Novo Nordisk, preserving its dominant position in the GLP-1 space was a strategic imperative.

Shortly after his appointment, the new CEO launched a comprehensive restructuring plan. The aim: by end of 2026, to save approximately 8 billion Danish kroner annually (about $1.26 billion) and thereby free up resources to invest in core growth areas. 

The strategic logic driving the cuts is dual-fold: a “subtractive” streamlining and an “additive” reinvestment. Novo Nordisk is abandoning non-core research avenues—including stopping its R&D in cell therapies for type 1 diabetes, Parkinson’s and heart failure—and laying off nearly all 250 employees from that unit. Simultaneously, the company is reinvesting in its diabetes and obesity franchises: a case in point being the acquisition of Akero Therapeutics (via $4.7 billion cash) for its Phase III FGF21 analogue tackling metabolic-associated steatohepatitis (MASH). This “one streamlines, one invests” dynamic signals an effort to amplify core strengths.

Most of the job cuts will affect the company’s home base: of the total, about 5,000 jobs in Denmark will be eliminated, making it the most affected region. For a century-old company, this redesign is not simply about headcount reduction—it reflects an ambition to reconfigure decision-making flows and shift toward a leaner, faster-paced organization capable of responding to a consumer-driven obesity market. 

The move at Novo Nordisk also mirrors a larger trend in big-pharma: facing escalating R&D costs, tighter regulatory regimes and heightened competition, many firms are reallocating from broad expansion to strategic focus. In the first half of 2025 alone, six major players combined announced job reductions exceeding 39,000. 

From an investment-oriented vantage, the repercussions are immediate. The announcement triggered a short-term uptick in share price, but the real test lies ahead: can the company convert leaner cost structure into renewed growth? With its GLP-1 drugs still performing strongly—three semaglutide products generated DKK 1127.56 billion (~US $175.45 billion) in the first half—the key metric will be whether this restructuring yields commercial acceleration rather than just cost savings.

From a governance and management perspective, Doustdar’s early message sets the tone: “Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven… It requires a shift in mindset so that we can be faster and more agile.” 

However, the road ahead is far from smooth. While the company commands a commanding portfolio, it must fend off advances by rivals such as Eli Lilly, tackle pricing and reimbursement pressures, and accelerate pipeline innovation. Without simultaneous advances in those areas, the job cuts may be seen as reactive rather than transformative.

As the pharmaceutical industry enters a new phase of structural realignment, Novo Nordisk’s reduction-plus-investment strategy may become emblematic of the shift from “expansion-driven growth” to “efficiency-driven growth.” For industry leaders and investors alike, the focus now turns to execution: Will fewer resources deployed more intelligently yield sustainable advantage? Novo Nordisk has taken the first visible step—but the long-term payoff remains to be proven.